AZD0530 in Mild Alzheimer’s Disease

“My colleagues and I were honored to be able to test this important therapeutic idea developed in basic research. Many of us have been personally touched by Alzheimer’s. We are so grateful to those who participated in this study.”

Chris van Dyck, M.D.
CONNECT Principal Investigator
Professor of Psychiatry, Neurology, and Neuroscience
Director, Alzheimer’s Disease Research Unit
Director, Yale Alzheimer’s Disease Research Center
Director, Division of Aging and Geriatric Psychiatry Yale School of Medicine
San Francisco VA Medical Center


On behalf of Yale University and the Alzheimer’s Therapeutic Research Institute (ATRI), we want to thank everyone for their participation in the FYN (Connect) study to evaluate the drug AZD0530 treatment was found to be safe and well-tolerated by most individuals at the doses tested (100 or 125mg daily).

However, treatment with AZD0530, did not demonstrate any benefit for the primary aim of the study, which was to preserve brain function as measured by the PET scans. It also did not show an advantage in the assessments of memory and daily functioning. Additional analyses are in progress, and the results will be reported to all clinical site, principal investigators.